<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02269865</url>
  </required_header>
  <id_info>
    <org_study_id>28486</org_study_id>
    <nct_id>NCT02269865</nct_id>
  </id_info>
  <brief_title>Children's Health Research Institute(CHRI), Stanford Lucile Packard Children Hospital (LPCH) Protocol on Myotonic Dystrophy</brief_title>
  <acronym>CHRI</acronym>
  <official_title>Defining and Managing the Neuropsychological Abnormalities of Myotonic Dystrophy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study to focus on the defining and managing the neuropsychological abnormalities of myotonic&#xD;
      dystrophy and to find out if the neuropsychological abnormalities have any correlation with&#xD;
      changes seen on Magnetic Resonance Imaging.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Given the prevalence of DM, and assistance from The Myotonic Dystrophy Foundation (letter),&#xD;
      we anticipate full recruitment of 8-17 year old subjects with DM1. The genetic counselor will&#xD;
      help recruit 20 DM1 subjects, and 20 comparably aged controls, all of whom will complete MRI&#xD;
      and neuropsychological tests. We anticipate full participation in evoked potential and blood&#xD;
      tests, but estimate 30% will permit a lumbar puncture for CSF evaluation - done at the LPCH&#xD;
      Ambulatory Procedure Unit with sedation as necessary. In total 40 MRIs will be done over 2&#xD;
      years, or 20 annually. Testing of Subjects&#xD;
&#xD;
      All neuropsychological evaluations will be performed in the morning in attempt to standardize&#xD;
      wakefulness and stamina. Dr. Day's assessment of clinical status (~45 min) utilizes the&#xD;
      Stanford myotonic dystrophy questionnaire, the University of Rochester MDHI, and the muscular&#xD;
      impairment rating scale (MIRS)57, and records vital signs, current medications, spirometer,&#xD;
      and disease history and progression. Given the frequency of sleep disorders in DM, subjects&#xD;
      will complete the Affiliated Sleep Questionnaire, an online collection of extensive&#xD;
      information in standardized format (see letter Dr. Mignot). After the clinical and&#xD;
      neuropsychological assessments the subject and family members will have lunch prior to the&#xD;
      MRI(75 min). In the mid-afternoon subjects will have evoked potentials in the&#xD;
      Electrodiagnostics Lab(~90 min) followed by a lumbar puncture (if consenting) and blood draw&#xD;
      in the LPCH APU(90 min). Subjects return home the same day, and Ms. Paulose contacts them&#xD;
      several days later for feedback.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Define the neuropsychological abnormalities in Myotonic Dystrophy type 1</measure>
    <time_frame>2 years</time_frame>
    <description>The outcome of these studies will determine detailed spatial localization of white matter changes in DM1 children for the first time, and will establish a quantitative baseline with which future studies can determine the time course of the changes. The outcome results will determine whether functional abnormalities (fMRI, neuropsychological function, and evoked potentials) increase as white matter integrity deteriorates, and will explore tract-specific alteration of these effects. Defining cellular pathophysiology and CNS biomarkers of neurological dysfunction in DM will determine disease mechanisms and treatment pathways, and facilitate design of clinical and preclinical studies.</description>
  </primary_outcome>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Myotonic Dystrophy Type 1</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood Samples and Cerebrospinal Fluid (CSF) samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        20 subjects with Myotonic Dystrophy type 1 aged 8 to 17 years and 20 controls who are&#xD;
        healthy volunteers or siblings of affected subjects.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  20 subjects with Myotonic Dystrophy type 1 aged 8 to 17 years and 20 controls who are&#xD;
             healthy volunteers or siblings of affected subjects.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John W Day, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>John W Day, MD, PhD</last_name>
    <phone>650-725-4341</phone>
    <email>jwday@stanford.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lucile Packard Childrens Hospital, Stanford</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94304</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>John W Day, MD, PhD</last_name>
      <phone>650-725-4341</phone>
      <email>jwday@stanford.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>December 4, 2013</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2014</study_first_posted>
  <last_update_submitted>October 16, 2014</last_update_submitted>
  <last_update_submitted_qc>October 16, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myotonic Dystrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

